FSIP1 and ductal breast carcinoma in situ: No difference was found in serum FSIP1 level between the ductal carcinoma in situ group and the invasive breast cancer group (6, 172 ± 2, 432 pg/ml vs. 4, 381 ± 3, 019 pg/ml, p = 0.3493, Table 3).